Neoplasm, Breast
14
4
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
14%
2 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (14)
Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)
TCM Therapy Program Impact on Breast Cancer Patients' Vital Energy
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
9-ING-41 in Patients with Advanced Cancers
Cooling Cap Trial to Prevent Permanent Chemotherapy-induced Alopecia in Breast Cancer Patients
Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment.
Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer